Skip to content

An evaluation of the safety and tolerability of different doses of Recombinant Anti HER2 for injection (open study section) HL02 in Chinese healthy male subjects compared HL02 with Herceptin ? the pharmacokinetics, safety ,tolerability and immunogenicity, randomized, double-blind, Comparative study of pharmacokinetics clinica

An evaluation of the safety and tolerability of different doses of Recombinant Anti HER2 for injection (open study section) HL02 in Chinese healthy male subjects compared HL02 with Herceptin ? the pharmacokinetics, safety ,tolerability and immunogenicity, randomized, double-blind, Comparative study of pharmacokinetics clinica

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RIC-17012372
Enrollment
Unknown
Registered
2017-08-15
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Breast Cancer

Interventions

one:HL02

Sponsors

First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Voluntary informed consent; 2. Healthy Chinese men (defined as health history, physical examination, vital signs, chest X-ray, 12-lead ECG and laboratory tests were found to have clinically significant abnormalities in); 3. Aged from 18 to 55 years; 4. Body mass index (BMI) from 18 to 28 kg/m2; 5. Weight 50 to 85 kg; 6. 14 days prior to randomization detected by echocardiography, LVEF within normal range(>50%); 7. Subjects agreed with him and his spouse or partner after the study medication within six months to study the use of reliable contraception use from the beginning, or the subject does not have fertility

Exclusion criteria

Exclusion criteria: 1. Complicated with hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, liver, mental, neurological, cancer and other serious illness or any clinical history of allergic diseases; 2. Within the first 6 months of the study drug used monoclonal antibodies or any biological agents; 3. Have a history of allergic reactions; 4. Use of prescription or non-prescription drugs, or dietary supplements, and the use of time within 5 half-lives of the drug or nutraceutical research or drug use before 2 weeks (time limited to whichever is longer)Chinese medicine Health Products required 28 days prior to study drug discontinued; 5. Use of research has a history of blood donation(=400ml) within the first 3 months of medication; 6. Before using the study medication within three months participated in any other clinical study; 7. Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody positive Treponema pallidum; 8. Have a history of drug abuse; within the first three months of daily smoking more than 5 and the first six months of weekly drinking alcohol is more than 14 units of alcohol (1 unit of alcohol = 360 mL or 45 mL of beer alcohol content of 40 % of spirits or wine 150 mL); 9. The researchers could not determine to follow program requirements, instructions and study restrictions, such as uncooperative attitude, unable to return to the center to do research or follow-up visits throughout the clinical study can not be completed and so on; 10. Alcohol and drug screening positive or the drug were used3 months before the experiment.

Design outcomes

Primary

MeasureTime frame
AUCinf;

Countries

China

Contacts

Public ContactYanhua Ding

First Hospital of Jilin University

dingyanhua2003@126.com+86 15943049468

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026